Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without H...

por Koyama, Kumiko, Ishikawa, Hirokazu, Abe, Manabu, Shiose, Yoshinobu, Ueno, Suguru, Qiu, Yang, Nakamaru, Kenji, Murakami, Masato
Publicado 2022

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Can...

por Kristof, Jessica, Sakrison, Kellen, Jin, Xiaoping, Nakamaru, Kenji, Schneider, Matthias, Beckman, Robert A, Freeman, Daniel, Spittle, Cindy, Feng, Wenqin
Publicado 2017

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study

por Fujiwara, Yutaka, Takeda, Masayuki, Yamamoto, Noboru, Nakagawa, Kazuhiko, Nosaki, Kaname, Toyozawa, Ryo, Abe, Chihiro, Shiga, Ryota, Nakamaru, Kenji, Seto, Takashi
Publicado 2018

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced...

por Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.
Publicado 2015